Chapter 2 Summary and Highlights
- Market Outlook
- Market Summary
Chapter 3 Market Overview
- Overview of Cardiovascular Disease
- Coronary Artery Disease
- Atherosclerosis
- Angina (Angina Pectoris)
- Acute Myocardial Infarction
- Medical Management
- Lifestyle Changes
- Diet Modification
- Smoking Cessation
- Pharmaceuticals
- Anticoagulants and Antiplatelet Drugs
- Major Drivers
- Coagulation Factors Targeted to Reduce Cvd
- The Global Burden of Cardiovascular Disease
- 2030 Global Burden of Cardiovascular Disease
- The Global Economic Burden of Cardiovascular Disease
- Sales Performance of Major Drugs in 2022
Chapter 4 Global Market for Anticoagulant Drugs
- Overview
- Products
- Low Molecular Weight Heparin
- Oral Anticoagulants (Vitamin K Antagonists)
- Global Anticoagulant Drugs Market Forecast
Chapter 5 Global Market for Antiplatelet Drugs
- Overview
- Products
- Oral Antiplatelets
- Global Antiplatelet Drugs Market Forecast
Chapter 6 Global Market for Thrombin Inhibitors
- Overview
- Products
- Direct Thrombin Inhibitors
- Thrombolytic Agents
- Direct Factor Xa Inhibitors
- Global Thrombin Inhibitors Market Forecast
Chapter 7 Global Market for Antithrombotic/Anticoagulant Drugs by Region
- Overview
- North America
- Europe
- Asia-Pacific
- Rest of the World
Chapter 8 Sustainability in the Market for Antithrombotic/Anticoagulant Drugs: An ESG Perspective
- Introduction to ESG
- Sustainability in Market for Antithrombotic/Anticoagulant Drugs: An ESG Perspective
- Key ESG Issues
- Consumer Attitudes Towards ESG
- Industry ESG Performance Analysis
- Case Study
- Concluding Remarks
Chapter 9 Clinical Trials and Patent Landscape
- Clinical Trials Analysis
- Patent Analysis
- Patent by Assignee
Chapter 10 M&A and Venture Funding Outlook
Chapter 12 Company Profiles
- Bayer AG
- Boehringer Ingelheim International GmbH
- Bristol Myers Squibb
- Daiichi Sankyo Co. Ltd.
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson Services Inc.
- Merck & Co. Inc.
- Pfizer Inc.
- Sanofi
List of Tables
Summary Table: Global Market for Antithrombotic/Anticoagulant Drugs, by Product Segment, Through 2028
Table 1: Standard Angina Pectoris Classification
Table 2: Top 20 Leading Causes of Death, 2019
Table 3: Estimated Deaths Due to Noncommunicable Diseases, by Sex and Disease, 2019
Table 4: Estimated Deaths Due to Cardiovascular Disease, by Sex and Disease, 2019
Table 5: Global Health Estimates, by Sex and WHO Region, 2019
Table 6: Estimated Deaths Due to Cardiovascular Disease, by Sex and Disease, 2030
Table 7: Estimated Deaths Due to Cardiovascular Disease, by Sex and WHO Region, 2030
Table 8: Economic Burden of NCDs in India, 2012-2030
Table 9: Praxbind (Idarucizumab) Drug Label
Table 10: Global Market for Thrombin Inhibitors Drugs, by Type, 2022
Table 11: Global Market for Anticoagulant Drugs, by Type, 2022
Table 12: Global Market for Antiplatelet Drugs, by Type, 2022
Table 13: Lovenox Drug Label
Table 14: Fragmin Drug Label
Table 15: Innohep Drug Label
Table 16: Global Market for Anticoagulant Drugs, by Region, Through 2028
Table 17: Global Market for Anticoagulant Drugs, by Type, Through 2028
Table 18: Global Market for Low Molecular Weight Heparin Anticoagulant Drugs, by Region, Through 2028
Table 19: Global Market for Oral Anticoagulant Drugs, by Region, Through 2028
Table 20: Plavix Drug Label
Table 21: Pletal Drug Label
Table 22: Effient Drug Label
Table 23: Global Market for Antiplatelets, by Type, Through 2028
Table 24: Global Market for Antiplatelets, by Region, Through 2028
Table 25: Global Market for Oral Antiplatelets, by Region, Through 2028
Table 26: Global IV Market for Antiplatelets, by Region, Through 2028
Table 27: Global Market for Thrombin Inhibitors, by Type, Through 2028
Table 28: Global Market for Thrombin Inhibitors, by Region, Through 2028
Table 29: Global Market for Direct Factor Xa Inhibitors, by Region, Through 2028
Table 30: Global Market for Direct Thrombin Inhibitors, by Region, Through 2028
Table 31: Global Market for Direct Thrombolytic Agents, by Region, Through 2028
Table 32: Global Market for Antithrombotic/Anticoagulant Drugs, by Region, Through 2028
Table 33: North American Market for Antithrombotic/Anticoagulant Drugs, by Country, Through 2028
Table 34: North American Market for Antithrombotic/Anticoagulant Drugs, by Type, Through 2028
Table 35: North American Market for Anticoagulant Drugs, by Type, Through 2028
Table 36: North American Market for Antiplatelets, by Type, Through 2028
Table 37: North American Market for Thrombin Inhibitors, by Type, Through 2028
Table 38: European Market for Antithrombotic/Anticoagulant Drugs, by Country, Through 2028
Table 39: European Market for Antithrombotic/Anticoagulant Drugs, by Type, Through 2028
Table 40: European Market for Anticoagulant Drugs, by Type, Through 2028
Table 41: European Market for Antiplatelets, by Type, Through 2028
Table 42: European Market for Thrombin Inhibitors, by Type, Through 2028
Table 43: Asia-Pacific Market for Antithrombotic/Anticoagulant Drugs, by Country, Through 2028
Table 44: Asia-Pacific Market for Antithrombotic/Anticoagulant Drugs, by Type, Through 2028
Table 45: Asia-Pacific Market for Anticoagulant Drugs, by Type, Through 2028
Table 46: Asia-Pacific Market for Antiplatelets, by Type, Through 2028
Table 47: Asia-Pacific Market for Thrombin Inhibitors, by Type, Through 2028
Table 48: Rest of the World Market for Antithrombotic/Anticoagulant Drugs, by Type, Through 2028
Table 49: Rest of the World Market for Anticoagulant Drugs, by Type, Through 2028
Table 50: Rest of the World Market for Antiplatelets, by Type, Through 2028
Table 51: Rest of the World Thrombin Inhibitors Drugs Market, by Type, Through 2028
Table 52: Key Focus Areas in ESG Metrics: Market for Antithrombotic/Anticoagulant Drugs
Table 53: Typical ESG Factors in Pharmaceuticals
Table 54: Net-Zero GHG Commitments by Major Antithrombotic/Anticoagulant Drug Manufacturing Companies
Table 55: ESG Rankings for Major Antithrombotic/Anticoagulant Drug Manufacturing Companies, 2023*
Table 56: CDP Scope Card for Major Antithrombotic/Anticoagulant Drug Manufacturing Companies, 2022
Table 57: Selected Thrombin Drugs in Clinical Trials, as of 2023
Table 58: Selected Granted Thrombosis Treatment Drugs in Clinical Trials, as of 2023
Table 59: Patents Issued on Anticoagulant Drugs, by Assignee Company, 2018-2022
Table 60: Patents Issued on Thrombin Inhibitor Drugs, by Assignee Company, 2018-2022
Table 61: Patents Issued on Antiplatelet Drugs, by Assignee Company, 2018-2022
Table 62: Global Market for Antithrombotic/Anticoagulant Drugs’ Recent Mergers and Acquisitions
Table 63: Global Market for Antithrombotic/Anticoagulant Drugs Revenue Analysis, 2022
Table 64: Global Market for Antithrombotic/Anticoagulant Drugs Key Product Portfolio, 2022
Table 65: Global Thrombin Inhibitors Drugs Market Revenue Analysis, 2022
Table 66: Global Anticoagulants Drug Market Revenue Analysis, 2022
Table 67: Global Antiplatelet Drugs Market Revenue Analysis, 2022
Table 68: Bayer AG: Marketed Products
Table 69: Bayer AG: Key Financials, 2021 and 2022
Table 70: Bayer AG: Key Developments, 2022 and 2023
Table 71: Boehringer Ingelheim: Selected Key Developments, 2019-2021
Table 72: Bristol-Myers Squibb: Key Developments, 2020 and 2021
Table 73: Daiichi Sankyo: Product Information
Table 74: Daiichi Sankyo: Annual Revenue, 2020-2022
Table 75: Daiichi Sankyo: Key Developments, 2018-2023
Table 76: Roche: Financials, 2021 and 2022
Table 77: Roche: Revenues, by Business Segment, 2016-2021
Table 78: Roche: Product Portfolio
Table 79: Roche: Diagnostics Patient Monitoring Product Portfolio
Table 80: Roche: Recent Developments, 2019-2022
Table 81: Johnson & Johnson: Products Portfolio for Antithrombotic/Anticoagulant Drugs Treatment
Table 82: Johnson & Johnson: Financials, 2021
Table 83: Johnson & Johnson: Product Portfolio
Table 84: Johnson & Johnson: Recent Developments and Strategies, 2017-2022
Table 85: Merck & Co. Inc.: Products Portfolio for Antithrombotic/Anticoagulant Drug Treatment
Table 86: Merck & Co. Inc.: Financial Performance, 2018-2022
Table 87: Pfizer Inc.: Product Segments
Table 88: Pfizer Inc.: Key Financials, 2021
Table 89: Sanofi: Products Portfolio for Antithrombotic/Anticoagulant Drugs Treatment
Table 90: Sanofi: Business Segments
Table 91: Sanofi: Financial Performance,2021 and 2022
Table 92: Sanofi: Key Developments, 2019-2023
Table 93: Government Regulatory Agencies and Professional Organizations Associated with Cardiac Biomarkers
List of Figures
Summary Figure: Global Market for Antithrombotic/Anticoagulant Drugs, by Product Segment, 2020-2028
Figure 1: Global Distribution of Male Deaths Caused by Cardiovascular Disease, by Age Group, 2019
Figure 2: Global Distribution of Male Deaths Caused by Cardiovascular Disease, 2019
Figure 3: Global Distribution of Female Deaths Caused by Cardiovascular Disease, by Age Group, 2019
Figure 4: Global Distribution of Female Deaths Caused by Cardiovascular Disease, 2019
Figure 5: Global Distribution of Male Deaths Caused by Cardiovascular Disease, by Age Group, 2030
Figure 6: Global Distribution of Male Deaths Caused by Cardiovascular Disease, 2030
Figure 7: Global Distribution of Female Deaths Caused by Cardiovascular Disease, by Age Group, 2030
Figure 8: Global Distribution of Female Deaths Caused by Cardiovascular Disease, 2030
Figure 9: Projected Total Costs of Cardiovascular Disease in the United States, 2015-2030
Figure 10: Global Market for Antithrombotic/Anticoagulant Drugs, by Region
Figure 11: Global Market Shares of Antithrombotic/Anticoagulant Drugs, by Region, 2022
Figure 12: How a Strong ESG Proposition Benefits Businesses
Figure 13: Global ESG-Adoption Level Across All the Industries, 2021 and 2022
Figure 14: The Ten Business Sustainability Trends Identified for 2022
Figure 15: Pfizer Inc.'s Most Material ESG Issues, 2020
Figure 16: Global Market Shares of Antithrombotic/Anticoagulant Drugs, by Company, 2022
Figure 17: Global Market Shares of Thrombin Inhibitors Drugs, by Company, 2022
Figure 18: Global Market Shares of Anticoagulant Drugs, by Company, 2022
Figure 19: Global Market Shares of Antiplatelet Drugs, by Company, 2022
Figure 20: Boehringer Ingelheim: Annual Revenue, 2021 and 2022
Figure 21: Boehringer Ingelheim: Revenue Share, by Business Segment, 2021 and 2022
Figure 22: Boehringer Ingelheim: Revenue Share, by Region, 2021 and 2022
Figure 23: Bristol-Myers Squibb: Revenue Share, by Region/Country, 2022
Figure 24: Daiichi Sankyo: Market Share, by Region/Country, 2022
Figure 25: Roche: Annual Revenue, 2021 and 2022
Figure 26: Roche: Market Share, by Business Segment, 2022
Figure 27: Roche: Revenue Share, by Business Segment, 2021
Figure 28: Roche: Revenue Share, by Region/Country, 2021
Figure 29: Johnson & Johnson: Financials, 2017-2021
Figure 30: Johnson & Johnson: Revenue Share, by Region/Country, 2021
Figure 31: Johnson & Johnson: Revenue Share, by Business Segment, 2021
Figure 32: Merck & Co. Inc.: Revenue Share, by Business Segment, 2022
Figure 33: Merck & Co. Inc.: Revenue Share, by Region, 2022
Figure 34: Pfizer Inc.: Revenue Share, by Region, 2021
Figure 35: Pfizer Inc.: Revenue Share, by Business Segment, 2021
Figure 36: Sanofi: Net Sales Share, by Business Segment, 2022
Figure 37: Sanofi: Net Sales Share, by Region/Country, 2022
